China says 1 billion COVID vaccine doses administered
Beijing plans to fully vaccinate 40 percent of the country’s nearly 1.4 billion people by the end of this month.
China has announced that more than one billion doses of the COVID-19 vaccine have been administered in the country, as the world’s most populous nation accelerated its immunisation programme.
The announcement by the National Health Commission (NHC) comes after the number of shots administered globally surpassed 2.5 billion on Friday, according to an AFP count from official sources.
The NHC did not say how many people had been vaccinated. As elsewhere, most of the vaccines in China are given in two doses.
Keep readinglist of 3 items
‘The virus knows no borders. Neither should our solidarity’
Australia takes wine dispute with China to WTO as sales plunge
The pace of vaccinations has accelerated in the country of 1.4 billion people after a slow start. The total number of doses given doubled from 500 million in less than a month, according to government tallies.
A lack of transparency and previous vaccine scandals have also led to resistance among residents.
Authorities have set an ambitious target of fully vaccinating 40 percent of the country’s nearly 1.4 billion people by the end of this month.
Incentives for vaccines
Some provinces are offering vaccines for free to encourage people to roll up their sleeves. Residents in central Anhui province have been given free eggs, while some living in Beijing have received shopping coupons.
A recent outbreak of the more contagious Delta variant of the virus in the southern city of Guangzhou has also served as a wake-up call for many dragging their feet.
China reported 23 new coronavirus cases on Sunday.
The country has four conditionally approved vaccines, whose published efficacy rates remain behind rival jabs by Pfizer-BioNTech and Moderna, which have 95 percent and 94 percent success rates respectively.
China’s Sinovac previously said trials of its shot in Brazil showed around 50 percent efficacy in preventing infection and 80 percent in preventing cases requiring medical intervention.
Sinopharm’s two vaccines have efficacy rates of 79 percent and 72 percent respectively, while the overall efficacy for CanSino’s stands at 65 percent after 28 days.
Regulators have not approved any non-Chinese vaccines so far, although they appear to be moving towards doing so for the one developed by Pfizer and BioNTech.
China is expected to produce more than three billion vaccine doses this year, state news agency Xinhua reported in April.
Health authorities have not said when China will reach herd immunity or what proportion of its vaccine doses will be sold abroad.